Last edition
News about "cerebrospinal fluid "
Acumen Announces New Findings from Phase 1 INTERCEPT-AD Study at AAIC 2024
Acumen Pharmaceuticals, Inc. has published new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193).
Cerebrospinal Fluid | 29/07/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members